Intellia Therapeutics Inc (NTLA)
21.18
-0.14
(-0.66%)
USD |
NASDAQ |
Apr 19, 12:50
Intellia Therapeutics Enterprise Value: 1.137B for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | 1.137B |
| April 17, 2024 | 1.154B |
| April 16, 2024 | 1.184B |
| April 15, 2024 | 1.291B |
| April 12, 2024 | 1.420B |
| April 11, 2024 | 1.491B |
| April 10, 2024 | 1.486B |
| April 09, 2024 | 1.594B |
| April 08, 2024 | 1.519B |
| April 05, 2024 | 1.469B |
| April 04, 2024 | 1.488B |
| April 03, 2024 | 1.489B |
| April 02, 2024 | 1.500B |
| April 01, 2024 | 1.704B |
| March 28, 2024 | 1.732B |
| March 27, 2024 | 1.685B |
| March 26, 2024 | 1.612B |
| March 25, 2024 | 1.666B |
| March 22, 2024 | 1.674B |
| March 21, 2024 | 1.745B |
| March 20, 2024 | 1.758B |
| March 19, 2024 | 1.743B |
| March 18, 2024 | 1.718B |
| March 15, 2024 | 1.808B |
| March 14, 2024 | 1.733B |
| Date | Value |
|---|---|
| March 13, 2024 | 1.843B |
| March 12, 2024 | 1.758B |
| March 11, 2024 | 1.927B |
| March 08, 2024 | 1.968B |
| March 07, 2024 | 1.973B |
| March 06, 2024 | 1.966B |
| March 05, 2024 | 1.995B |
| March 04, 2024 | 2.201B |
| March 01, 2024 | 2.227B |
| February 29, 2024 | 2.175B |
| February 28, 2024 | 2.240B |
| February 27, 2024 | 2.069B |
| February 26, 2024 | 1.746B |
| February 23, 2024 | 1.596B |
| February 22, 2024 | 1.700B |
| February 21, 2024 | 1.671B |
| February 20, 2024 | 1.697B |
| February 16, 2024 | 1.754B |
| February 15, 2024 | 1.735B |
| February 14, 2024 | 1.718B |
| February 13, 2024 | 1.548B |
| February 12, 2024 | 1.841B |
| February 09, 2024 | 1.713B |
| February 08, 2024 | 1.642B |
| February 07, 2024 | 1.512B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
197.07M
Minimum
Mar 16 2020
12.46B
Maximum
Sep 03 2021
2.956B
Average
2.324B
Median
Enterprise Value Benchmarks
| Moderna Inc | 30.45B |
| Regeneron Pharmaceuticals Inc | 89.21B |
| NeuroMetrix Inc | -10.75M |
| Repligen Corp | 8.587B |
| Pacific Biosciences of California Inc | 652.53M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -132.16M |
| Revenue (Quarterly) | -1.917M |
| Total Expenses (Quarterly) | 137.98M |
| EPS Diluted (Quarterly) | -1.46 |
| Earnings Yield | -25.54% |
| Normalized Earnings Yield | -25.54 |